Evidence map›Paper›PMID 34085761›Full record

ArticleClinical and translational science2021

Tissue pharmacokinetics of DHP107, a novel lipid-based oral formulation of paclitaxel, in mice and patients by positron emission tomography.

Byung Seok Moon, Hyun Soo Park, Jung Sunwoo, In-Hyun Lee, Anhye Kim, Seol Ju Moon, Heechan Lee, Min Hee Son, Su Bin Kim, Sun Mi Park and 6 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Byung Seok MoonDepartment of Nuclear Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
Hyun Soo ParkDepartment of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea.
Jung SunwooDepartment of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
In-Hyun LeePan-gyo Research Laboratory, Daehwa Pharmaceutical Co. Ltd, Seongnam, Korea.
Anhye KimDepartment of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Seol Ju MoonBiomedical Research Institute, Chonbuk National University Hospital, Jeonju, Korea.
Heechan LeeDepartment of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Min Hee SonPan-gyo Research Laboratory, Daehwa Pharmaceutical Co. Ltd, Seongnam, Korea.
Su Bin KimDepartment of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea.
Sun Mi ParkDepartment of Nuclear Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
Sang-Keun WooDivision of RI-Convergence Research, Korea Institute Radiological and Medical Sciences, Seoul, Korea.
Jun-Hee JangPan-gyo Research Laboratory, Daehwa Pharmaceutical Co. Ltd, Seongnam, Korea.
Bom Sahn KimDepartment of Nuclear Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
Jee Hyun KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea.
Sang Eun KimDepartment of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea.
Howard LeeDepartment of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Dae Hwa Pharm (South Korea) · KREwha Womans University · KRSeoul National University Bundang Hospital · KRAdvanced Institute of Convergence Technology · KRCHA University · KRJeonbuk National University Hospital · KRKorea Institute of Radiological and Medical Sciences · KRSeoul National University Hospital · KRUlsan College · KR

Funding

Basic Science Research Program through the National Research Foundation of Korea 2018R1D1A1A02085705Korea Health Technology R&D Project through the Korea Health Industry Development Institute HI16C0947
6 · The paper itself

Abstract

DHP107 is a newly developed lipid-based oral formulation of paclitaxel. We evaluated the in vivo tissue pharmacokinetics (PKs) of DHP107 in mice and patients using positron emission tomography (PET). Radioisotope-labeled [

Indexed as

Administration, OralAdultAnimalsBreast NeoplasmsDrug DevelopmentFemaleFluorine RadioisotopesHumansMiceMolecular ImagingPaclitaxelPositron-Emission TomographyRadiopharmaceuticalsXenograft Model Antitumor AssaysFluorine-18Fluorine RadioisotopesPaclitaxelRadiopharmaceuticals

Identifiers

PMID34085761
PMCPMC8504807
OpenAlexW3165618301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.